Collectively, these findings show that RAD51 inhibition-mediated IRF1 upregulation, a downstream component of ATR/Chk1 signaling, is a critical mechanism underlying PD-L1 expression regulation in cancer cells. The gene discussed is CD274; the disease is cancer.